Sio Gene Therapies

$2.86
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.03 (-1.04%) Today

$0.00 (0.00%) As of 9:37 PM UTC after-hours

Why Robinhood?

You can buy or sell SIOX and other stocks, options, and ETFs commission-free!

About SIOX

Sio Gene Therapies Inc. Common Stock, also called Sio Gene Therapies, is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of gene therapies for neurological diseases. Its product pipeline focus on Parkinson's Disease, GM1 gangliosidosis, and GM2 gangliosidosis such as Tay-Sachs disease and Sandhoff disease. Axovant operates through seven wholly owned subsidiaries and also has business operations in Basel, Switzerland and New York, NY. The company was founded on October 31, 2014 and is headquartered in New York, NY. The listed name for SIOX is Sio Gene Therapies Inc. Common Stock.

CEO

Pavan Cheruvu

Employees

Headquarters

New York, New York

Founded

2014

Market Cap

138.62M

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

1.17M

High Today

$3.06

Low Today

$2.81

Open Price

$2.92

Volume

1.41M

52 Week High

$4.15

52 Week Low

$1.90

Collections

SIOX Earnings

-$1.23

-$0.82

-$0.41

$0.00

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Q1 FY21

Q2 FY21

Q3 FY21

Estimated

— per share

Actual

Expected Feb 10, Pre-Market